// App-Quantinova.ai

2136 : Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components

Researchers

Presenter

  • Arthur Kavanaugh

Principal Investigators

  • Laura Coates

  • Joseph Merola

  • Philip J Mease

  • Miroslawa Nowak

  • Subhashis Banerjee

  • Lauren Hippeli

  • Tom Lehman

Medical Centers

  • University of California, San Diego, La Jolla, CA

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03881059

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved